14.07USD-1.78%Mkt Cap: 764.02M USDP/E: —Last update: 2026-05-26
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treat…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap764.02M USD
Enterprise Value326.37M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-695.98M USD
Revenue/Share—
Last Price14.07 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.18
PEG—
EV/EBITDA-0.95
EV/Revenue—
P/S—
P/B-3.54
EPS (TTM)-70.40
EPS (Forward)-3.60
52W Range
3.30017% of range65.80
52W High65.80 USD
52W Low3.300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE423.57%
ROA-149.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.71M USD
CapEx (TTM)941.00K USD
FCF Margin—
FCF Yield-25.62%
Net Debt-488.59M USD
Net Debt/EBITDA1.43
Balance Sheet
Debt/Equity-0.02
Current Ratio31.15
Quick Ratio30.57
Book Value/Sh-4.2440 USD
Cash/Share9.071 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateSep 19, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)37.88 USD
Target Range18.00 USD – 50.00 USD
# Analysts8
Ownership
Shares Out.54.19M
Float43.71M
Insiders4.29%
Institutions69.39%
Short Interest
Short Ratio4.0d
Short % Float10.94%
Short % Out.9.15%
Shares Short4.96M
Short (prev mo.)5.69M
Technical
SMA 5014.97 (-6.0%)
SMA 20020.46 (-31.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)925.33K
Avg Vol (10d)1.01M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—